Clinical Trials Logo

Recurrent Hematologic Malignancy clinical trials

View clinical trials related to Recurrent Hematologic Malignancy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02805075 Completed - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Start date: June 2016
Phase: Phase 1
Study type: Interventional

This pilot phase I trial studies the side effects and best dose of fructooligosaccharides in treating patients with blood cancer who are undergoing donor stem cell transplant. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Nutritional supplements such as fructooligosaccharides may reduce the incidence of graft-versus-host disease in patients with blood cancer undergoing donor stem cell transplant.

NCT ID: NCT01822509 Completed - Clinical trials for Myeloproliferative Neoplasm

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

Start date: May 16, 2013
Phase: Phase 1
Study type: Interventional

This phase I/Ib trial studies the side effects and best dose of ipilimumab or nivolumab in treating patients with cancers of the blood and blood-forming tissues (hematologic cancers) that have returned after a period of improvement (relapsed) after donor stem cell transplant. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.